Modest Population-Level Increases in Survival Observed After Implementation of Immune Checkpoint Inhibitors in the Treatment of Advanced NSCLC, Particularly Among the Older Patients
Findings from a large cohort of patients with advanced non-small cell lung cancer demonstrate substantially different gain in survival by age